Non-invasive biomarkers, due to their non-invasive and safe characteristics, hold significant potential for the diagnosis and prognosis of epilepsy. This review summarizes the research progress and future directions of non-invasive biomarkers for epilepsy, encompassing electrophysiological, imaging, biochemical, and genetic markers, and discusses biomarkers for specific types of epilepsy, such as structural lesion-related epilepsy, infection and inflammation-related epilepsy, autoimmune epilepsy, endocrine hormone-related epilepsy, and metabolic epilepsy, to facilitate their clinical application.
Parkinson’s disease is a common neurodegenerative disorder with continuously rising incidence rates. Existing pharmacological treatments have complications and cannot halt disease progression. Transcranial focused ultrasound stimulation (tFUS), as a novel neuromodulation technology, demonstrates unique advantages in Parkinson’s disease treatment. tFUS exerts multiple effects through mechanical mechanisms at multiple levels, including protecting dopaminergic neurons, regulating neurotransmitter systems, and improving neural circuit function. Preclinical studies have confirmed its potential in improving both motor and non-motor symptoms, and early clinical studies have shown good safety profiles. However, the clinical translation of tFUS still faces challenges such as parameter optimization and individualized treatment protocols, requiring validation of long-term efficacy through large-scale clinical trials.